BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, February 12, 2026
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 12, 2010
View Archived Issues
Dicerna Raises $25M Series B to Fund RNAi Cancer Program
Read More
Aegerion Re-Files $86M IPO to Back Cholesterol Drug
Read More
Amgen's Vectibix Disappoints in Head/Neck Cancer Trial
Read More
Other News To Note
Read More
Stock Movers
Read More
Clinic Roundup
Read More
Alectos to Study Alzheimer's Target in Merck $289M Deal
Alectos Therapeutics Inc. will receive up to $289 million in an up-front fee and milestone payments under a collaboration with Merck & Co. to study a potential non-amyloid approach to treat Alzheimer's disease. (BioWorld Today)
Read More
FDA Panel Gives Thumbs Up for Valeant Epilepsy Drug
Read More
